TNF and metabolic syndrome: Similar to other biochemicals in the circulation, ApoA-1 is sensitive to the doxorubicin-induced oxidative damage (84), leading to dyslipidemia and increased circulating TNF-α in the doxorubicin- injection animals (22, 75), resulting in cognitive impairment (84).